PTGS2 and neoplasm: TA treatment at doses of 5 or 10 mg/kg significantly reduced COX-2 levels in ascites macrophages by 85.57% and 78%, respectively (p < 0.0001 for both doses), and in tumor cells by 54.56% and 52.17% (p < 0.001; p < 0.01), respectively (Table 7).